Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Results from a collaboration between the Rabbitts Group (MRC Weatherall Institute of Molecular Medicine, WIMM) and the Russell group (Departments of Chemistry and Pharmacology) have recently been published in Nature Communications. The paper entitled ‘Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment’ describes a new approach using intracellular antibody fragments to block Protein-Protein Interactions (PPIs), use the fragments for target validation in disease models, and develop new small molecules against the PPI epitope.  The work by the Rabbitt and Russell Groups used the approach to identify RAS-binding compounds with the aim of developing potential treatments for RAS-dependent cancers. 

Find the full paper here https://www.nature.com/articles/s41467-018-05707-2

Similar stories

Collaboration in action - from a Pharmacology perspective

As part of the Medical Sciences Division's series on industry collaboration, Pharmacology's Associate Professor Sri Vasudevan shares the important of networking at conferences and listening to a range of views as vital building blocks that can lead to effective commercial partnerships.